Clinical Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Associated With Mutations in Plakophilin-2

Background— Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy characterized by right ventricular dysfunction and ventricular arrhythmias. A recent study reported mutations in PKP2, encoding the desmosomal protein plakophilin-2, associated with ARVD/C. The purpose of our study was to validate the frequency of PKP2 mutations in another large series of ARVD/C patients and to examine the phenotypic characteristics associated with PKP2 mutations. Methods and Results— DNA from 58 ARVD/C patients was sequenced to determine the presence of mutations in PKP2. Clinical features of ARVD/C were compared between 2 groups of patients: those with a PKP2 mutation and those with no detectable PKP2 mutation. Thirteen different PKP2 mutations were identified in 25 (43%) of the patients. Six of these mutations have not been reported previously; 4 occurred in multiple, apparently unrelated, families. The mean age at presentation was lower among those with a PKP2 mutation (28±11 years) than in those without (36±16 years) (P<0.05). The age at median cumulative symptom-free survival (32 versus 42 years) and at the median cumulative arrhythmia-free survival (34 versus 46 years) was lower among patients with a PKP2 mutation than among those without a PKP2 mutation (P<0.05). Inducibility of ventricular arrhythmias on an electrophysiology study, diffuse nature of right ventricular disease, and presence of prior spontaneous ventricular tachycardia were identified as predictors of implanted cardioverter/defibrillator (ICD) intervention only among patients without a PKP2 mutation (P<0.05). Conclusions— Our study highlights the clinical relevance of PKP2 mutations in ARVD/C. Presence of a PKP2 mutation in ARVD/C correlates with earlier onset of symptoms and arrhythmia. Patients with a PKP2 mutation experience ICD interventions irrespective of the classic risk factors determining ICD intervention in ARVD/C patients.

[1]  G. Danieli,et al.  Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. , 2005, European heart journal.

[2]  Gian Antonio Danieli,et al.  Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. , 2005, Cardiovascular Research.

[3]  Walter Birchmeier,et al.  Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy , 2004, Nature Genetics.

[4]  X. Jouven,et al.  Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.

[5]  H. Calkins,et al.  Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity: A Need to Broaden Diagnostic Criteria , 2004, Circulation.

[6]  H. Halperin,et al.  Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[7]  G. Breithardt,et al.  Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients , 2004, Circulation.

[8]  D. Corrado,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: , 2004, Journal of cardiovascular electrophysiology.

[9]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[10]  D. Malicier,et al.  Circumstances of Death and Gross and Microscopic Observations in a Series of 200 Cases of Sudden Death Associated With Arrhythmogenic Right Ventricular Cardiomyopathy and/or Dysplasia , 2003, Circulation.

[11]  S. Rosenheck,et al.  Arrhythmogenic Right Ventricular Dysplasia A Recessive Mutation in Desmoplakin Causes Arrhythmogenic Right Ventricular Dysplasia, Skin Disorder, and Woolly Hair , 2003 .

[12]  G. Danieli,et al.  Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. , 2002, American journal of human genetics.

[13]  M. S. Hamid,et al.  Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. , 2002, Journal of the American College of Cardiology.

[14]  G. Danieli,et al.  Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. , 2002, Journal of the American College of Cardiology.

[15]  S. Priori,et al.  Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia , 2002, Journal of cellular physiology.

[16]  W. Mckenna,et al.  Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. , 2001, Journal of the American College of Cardiology.

[17]  D. Stephan,et al.  Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). , 2001, Human molecular genetics.

[18]  G. Danieli,et al.  Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. , 2000, Journal of the American College of Cardiology.

[19]  A. Crosby,et al.  Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease) , 2000, The Lancet.

[20]  D. Corrado,et al.  CARDIOMYOPATHY Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment , 2022 .

[21]  D. Corrado,et al.  Screening for hypertrophic cardiomyopathy in young athletes. , 1998, The New England journal of medicine.

[22]  M. Davies,et al.  Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. , 1997, Journal of the American College of Cardiology.

[23]  F. Marcus,et al.  Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: A Review , 1995, Pacing and clinical electrophysiology : PACE.

[24]  A. Nava,et al.  Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. , 1994, British heart journal.

[25]  G. Breithardt,et al.  Standards for analysis of ventricular late potentials using high resolution or signal-averaged electrocardiography. A statement by a Task Force Committee between the European Society of Cardiology, the American Heart Association and the American College of Cardiology. , 1991, European heart journal.

[26]  D. Corrado,et al.  Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. , 1990, The American journal of medicine.

[27]  J. Gallagher,et al.  Long-term follow-up in patients with arrhythmogenic right ventricular disease. , 1989, European heart journal.

[28]  D. Corrado,et al.  Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.

[29]  R Frank,et al.  Right Ventricular Dysplasia: A Report of 24 Adult Cases , 1982, Circulation.

[30]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.